Haemonetics Corporation (HAE)
| Market Cap | 3.01B |
| Revenue (ttm) | 870.46M |
| Net Income (ttm) | 79.47M |
| Shares Out | 50.85M |
| EPS (ttm) | 1.55 |
| PE Ratio | 38.10 |
| Forward PE | 22.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $59.06 |
| Previous Close | $59.30 |
| Change ($) | -0.24 |
| Change (%) | -0.40% |
| Day's Open | 59.11 |
| Day's Range | 57.93 - 59.39 |
| Day's Volume | 523,486 |
| 52-Week Range | 49.26 - 142.11 |
BOSTON, July 9, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2022 financial results at 6:00 am EDT on Wednesday, Augus...
We believe that the stock price of Haemonetics, best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of around $86 it...
The stock price of Haemonetics, best known for its blood and plasma supplies and services, has seen a large 13% drop over the last ten trading days, and we believe the stock will likely rebound in the n...
Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.
One analyst upgrade in particular seemed to bring back the bulls.
Investors don't seem to be buying the company's rosy 2022 guidance.
Haemonetics (HAE) delivered earnings and revenue surprises of -31.34% and -0.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Haemonetics (NYSE:HAE) rose 2.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 33.33% over the past year to $0.46, which missed th...
BOSTON, May 13, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2021, which ended April 3, 2021, are available on its Investor Rel...
Continued benefits from the NexSys device and NexLynk DMS along with robust TEG devices sales are expected to have contributed to Haemonetics (HAE) fourth-quarter top line.
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, April 29, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, annou...
BOSTON, April 23, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2021 financial results at 6:00 am EDT on Thursday, ...
The stock price of Haemonetics, best known for its blood and plasma supplies and services, plunged over 36% in a single trading session yesterday. This can be attributed to one of its large customers - ...
BOSTON, April 19, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics" or the "Company"), a global medical technology company focused on delivering innovative medical solutions to dri...
Haemonetics stock, best known for its blood and plasma supplies and services, has fallen by 3.5% in the last week, while it is down 7% over the last ten days. HAE stock has been on a decline since it re...
Investor are optimistic about Haemonetics (HAE) on its continued Plasma franchise growth and huge potential of Hemostasis Management franchise.
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Seni...
BOSTON, March 1, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $425,000,000 aggregate principal...
BOSTON, Feb. 26, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Jefferies Plasma Summit on Thursday, March 11, 2021, at 10:45...
Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.
Haemonetics Corporation (HAE) CEO Christopher Simon on Q3 2021 Results - Earnings Call Transcript
Haemonetics (HAE) delivered earnings and revenue surprises of 19.12% and 6.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Haemonetics (NYSE:HAE) were flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 13.83% year over year to $0.81, which beat the estimate ...
BOSTON, Feb. 2, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal 2021, which ended December 26, 2020, are available on its Investor ...
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Jan. 22, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive better patient ...
BOSTON, Jan. 20, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) ("Haemonetics"), a global medical technology company focused on delivering innovative medical solutions to drive better patient ...
Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.
BOSTON, Jan. 5, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday, Februar...
With the Covid vaccine rollout accelerating, these companies will be big beneficiaries in the year ahead.
Haemonetics has sustainable growth levers in place that are underscored by key product offerings and recent liquidity preservation measures. The company remains insulated from larger names via their ext...
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $113 currently and it is, in fact, d...
Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities ...
Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.
Haemonetics Corporation (HAE) CEO Chris Simon on Q2 2021 Results - Earnings Call Transcript
Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Haemonetics (NYSE:HAE) fell 0.1% in pre-market trading after the company reported Q2 results.
BOSTON, Nov. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal 2021, which ended September 26, 2020, are available on its Investor...
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Oct. 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, Novem...
BOSTON, Oct. 2, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, toda...
With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at what should b...
BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conferen...
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?
Shares of plasma provider Haemonetics off highs as Needham says COVID-19 EUA not material to results
Shares of blood transfusion and plasma provider Haemonetics Inc. HAE, +2.34% were off their highs on Monday, after Needham analysts said news of an emergency use authorization for convalescent plasma as...
Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2020 Results - Earnings Call Transcript
About HAE
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides autom... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date May 9, 1991 |
| CEO Christopher Simon | Employees 2,708 |
| Stock Exchange NYSE | Ticker Symbol HAE |
Financial Performance
In 2021, Haemonetics's revenue was $870.46 million, a decrease of -11.94% compared to the previous year's $988.48 million. Earnings were $79.47 million, an increase of 3.85%.
Analyst Forecasts
According to 7 analysts, the average rating for Haemonetics stock is "Buy." The 12-month stock price forecast is 80.29, which is an increase of 35.95% from the latest price.